12:00 AM
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Azzalure abobotulinumtoxinA regulatory update

Ipsen and Galderma said Azzalure abobotulinumtoxinA was approved in Germany to treat moderate to severe glabellar lines (frown lines between the eyebrows) for aesthetic applications. Galderma plans to launch the neuromuscular blocking toxin, which acts by inhibiting the...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >